

## [Albendazole](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.1. Anthelmintics 6.1.4. Cysticidal medicines](#)

ATC codes: [P02CA03](#)

EMLc

Indication

Cysticercosis of central nervous system ICD11 code: [1F70.0](#)

INN

Albendazole

Medicine type

Chemical agent

List type

Complementary

Formulations

**Oral > Solid > tablet:** 400 mg (chewable, scored) ; 200 mg (chewable) (EMLc)

EML status history

First added in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Albendazole](#)

DrugBank

[Albendazole](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listings for albendazole 400 mg chewable tablets on the EML and EMLc be amended to specify that they be scored.

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of a new strength formulation (200 mg chewable tablets) to the EMLc for treatment of diseases caused by taeniid cestode cysts.